Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider, Premier Biotech (“Premier” or the “Company”), announced the acquisitions of NexScreen and TransMed. These strategic acquisitions expand Premier’s global footprint and online presence, enhance the Company’s product portfolio and deepen customer relationships across healthcare, government and workplace markets. NexScreen provides point-of-care diagnostic testing solutions to customers across the United States, Australia and New Zealand. TransMed offers a broad catalog of drug testing products and laboratory supplies to +1,000 direct customer accounts, supported by its e-commerce platform and an extensive international network of manufacturers, suppliers and resellers.
Read the full article: Premier Biotech Broadens Product Portfolio with NexScreen and TransMed Acquisitions //
Source: https://www.businesswire.com/news/home/20260618763382/en/Premier-Biotech-Broadens-Product-Portfolio-With-NexScreen-and-TransMed-Acquisitions